Filing search / Pulmatrix, Inc. / "Safety"

8-K

EX-99.1

PULM Pulmatrix, Inc.

13 Aug 24

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

9:05am

protocol where safety and preliminary efficacy of PUR3100 will be investigated in patients with acute migraine. The planned Phase 2 trial builds on the Phase … of PUR1800 for AECOPD, indicating PUR1800 was safe and well tolerated with no observed safety signals. The topline data, along with the results from

8-K

EX-99.1

PULM Pulmatrix, Inc.

15 May 24

Regulation FD Disclosure

9:00am

. Self-administered PUR3100 showed improved safety and tolerability relative to IV DHE. Pulmatrix previously received FDA’s acceptance of an IND … central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced publication of, “Safety

8-K

PULM Pulmatrix, Inc.

15 May 24

Regulation FD Disclosure

9:00am

is attached hereto as Exhibit 99.1, announcing publication of “Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry

8-K

EX-99.1

ma2fe6sghl1

10 May 24

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

9:05am

8-K

EX-99.1

082vw3tk9dsl5169

28 Mar 24

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

9:05am

8-K

EX-10.1

9byfe

8 Jan 24

Entry into a Material Definitive Agreement

9:00am

8-K

EX-99.1

s8x9awemx s1ndx6

9 Nov 23

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

9:05am

8-K

EX-99.1

d69gli5 m5ca

10 Aug 23

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

9:05am

8-K

EX-99.1

i1bj2d

11 Jul 23

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

9:05am

8-K

EX-99.1

ukqw9ijhen0pxi

12 May 23

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

9:05am

8-K

EX-99.1

lzrwner5u sjkzydkmxf

30 Mar 23

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

9:05am

8-K

EX-99.1

d6cjrhtzkir3xg3u

14 Nov 22

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

6:17am